(Q37600501)

English

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

scientific article published on March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J B Vermorken

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

F Peyrade

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

J Krauss

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

R Mesía

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

E Remenar

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

T C Gauler

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

U Keilholz

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

J P Delord

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

P Schafhausen

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

J Erfán

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

T H Brümmendorf

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

L Iglesias

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

U Bethe

13

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C Hicking

14

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

P M Clement

15

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

1 March 2014

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

25

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

682-688

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Roles of integrins in tumor angiogenesis and lymphangiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

23 August 2017

Integrins as therapeutic targets.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

6 September 2017

Optimal treatment for recurrent/metastatic head and neck cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

6 September 2017

Selection designs for pilot studies based on survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933250

1 September 2018

Identifiers

10.1093/ANNONC/MDU003

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37600501&oldid=2146945794"